Skip to content
initiative Octalfa
Engagés pour l'innovation et la santé
initiative Octalfa
  • Home
  • About us
  • Our history
  • Our team
  • Newsroom
  • Contact
  • fr
  • Home
  • About us
  • Our history
  • Our team
  • Newsroom
  • Contact
  • fr

Newsroom

You are here:
  1. Home
  2. Newsroom
Orphelia Pharma

ORPHELIA Pharma opens its operating pharmaceutical establishment in France

ORPHELIA Pharma opens its operating pharmaceutical establishment in France

https://initiative-octalfa.eu/wp-content/uploads/2021/02/2021-PR-ORPHELIA-Etab-pharma-280121-en-final.pdf

AACR annual meeting 2021

AACR annual meeting 2021

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.

https://www.orega-biotech.com/
Orphelia Pharma

ORPHELIA Pharma awarded a grant from the region Île-de-France to support business activity development in Europe and in the US

ORPHELIA Pharma awarded a grant from the region Île-de-France to support business activity development in Europe and in the US

https://initiative-octalfa.eu/wp-content/uploads/2021/01/2021-PR-ORPHELIA-PMUP-210126_EN.pdf

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

https://amolytpharma.com/2021/01/06/amolyt-pharma-receives-orphan-drug-designation-for-azp-3601-for-the-potential-treatment-of-hypoparathyroidism/
Orphelia Pharma

ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

https://initiative-octalfa.eu/wp-content/uploads/2021/01/PR-Ethypharm-Orphelia_EN_FV_clean.pdf
Fondation

Six new projects supported by our Foundation and our Endowment Fund

Six new projects supported by our Foundation and our Endowment Fund

During the Board of Directors in December 2020, we supported 6 new projects: concerts at the hospital with the CIMCL, a saddle adapted for donkey rides with Handiane, computer equipment and furniture for AKA.MA, school for deaf children and the centers for disabled people Les Roseaux, Orchidées Blanches and Anyma.

https://initiative-octalfa.eu/wp-content/uploads/2021/01/201215-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Announces Research Collaboration with PeptiDream

https://amolytpharma.com/2020/12/08/amolyt-pharma-announces-research-collaboration-with-peptidream/

Newsletter December 2020

Newsletter December 2020

This newsletter outlines the last projects we have supported during the second half of 2020

https://initiative-octalfa.eu/wp-content/uploads/2020/12/Lettre-IDTA10-EN.pdf
Fondation

Three new projects supported by our Foundation

Three new projects supported by our Foundation

The 22nd of october 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support the Moebius Syndrome Association France, Au-delà de nos handicaps and the Saint-Vincent medicalized foster home

https://initiative-octalfa.eu/wp-content/uploads/2020/11/201025-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog AZP-3601

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog AZP-3601

https://amolytpharma.com/2020/10/14/amolyt-pharma-doses-first-subject-in-phase-1-clinical-trial-of-parathyroid-hormone-analog-azp-3601-for-hypoparathyroidism/
Orphelia Pharma

ORPHELIA Pharma to organize a Symposium at the SIOP 2020 congress on Friday October 16th

ORPHELIA Pharma to organize a Symposium at the SIOP 2020 congress on Friday October 16th

https://initiative-octalfa.eu/wp-content/uploads/2020/10/2020-Orphelia-Kimozo-SIOP-_en.pdf
Orphelia Pharma

ORPHELIA announces the inclusion of the first patient in a clinical study evaluating Kimozo, its pediatric formulation of temozolomide

ORPHELIA announces the inclusion of the first patient in a clinical study evaluating Kimozo, its pediatric formulation of temozolomide

https://initiative-octalfa.eu/wp-content/uploads/2020/10/2020-Orphelia-Kimozo-FPI-bioeq-_en.pdf

Meet us at BIO-Europe 2020, October 26-29

Meet us at BIO-Europe 2020, October 26-29

Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020.
BIO-Europe is Europe’s largest partnering conference serving the global biotech industry.Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.

https://www.orega-biotech.com/news/meet-us-at-bio-europe-20/

ORPHELIA will attend and support the annual SIOP Congress 2020 

ORPHELIA will attend and support the annual SIOP Congress 2020 

This event aims to bring together the oncology community and share the latest advances in pediatric oncology. Join the ORPHELIA Pharma virtual symposium to share on innovation in the use of temozolomide in children, which will take place on Friday October 16th between 9:15 AM and 9:35 AM (Ottawa time) by logging on to the SIOP website (SIOP-Congress.org).

http://www.orphelia-pharma.eu/news/orphelia-pharma-will-attend-and-support-the-annual-siop-congress-2020/
Fondation

Four new projects supported by our Foundation

Four new projects supported by our Foundation

The 10th of july 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support Plumes de vie, Quelle Histoire!, the Association Française du syndrome de Rett and the Association Française du syndrome d’Angelman.

https://initiative-octalfa.eu/wp-content/uploads/2020/08/200825-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Newsletter July 2020

Newsletter July 2020

This newsletter outlines the 12 projects we have supported during the first half of 2020

https://initiative-octalfa.eu/wp-content/uploads/2020/07/Lettre-IDTA9-EN-2.pdf

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma

https://initiative-octalfa.eu/wp-content/uploads/2020/06/Amolyt-Rebranding-Announcement-EN.pdf
Fondation

Nine new projects supported by our Foundation

Nine new projects supported by our Foundation

Since the beginning of the COVID-19 epidemic, our Corporate Foundation and our Endowment Fund have been attentive to the needs of the most deprived associations. Nine operations to support vulnerable people were conducted in March and April 2020.

https://initiative-octalfa.eu/wp-content/uploads/2020/05/200515-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Newsletter april 2020

Newsletter april 2020

Une courte lettre d’information en ces temps troublés pour vous indiquer que notre Fondation d’Entreprise et notre Fonds de Dotation restent mobilisés pour soutenir les projets associatifs dans le domaine du cancer et du handicap

https://initiative-octalfa.eu/wp-content/uploads/2020/06/Lettre-IDTA8.pdf
Fondation

Three new projects supported by our Foundation

Three new projects supported by our Foundation

The 19th of march 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Paris Newdance” with dance lesson for women affected by cancer, “Réseau Luciole” with a booklet about the surgical course of people with disabilities and “Sourire d’Onja” for a container that will send medical equipment from Reunion to Madagascar.

https://initiative-octalfa.eu/wp-content/uploads/2020/05/200515-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf
Orphelia Pharma

ORPHELIA announces the appointment of Laurent MARTIN as Chief Pharmaceutical Affairs Officer

ORPHELIA announces the appointment of Laurent MARTIN as Chief Pharmaceutical Affairs Officer

https://initiative-octalfa.eu/wp-content/uploads/2020/03/2020_LMA-EN-200311_final.pdf

First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary day

First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary day

https://initiative-octalfa.eu/wp-content/uploads/2020/03/OREGA-Biotech_PR_200310-1.pdf
Orphelia Pharma

ORPHELIA Pharma fund raising

ORPHELIA Pharma fund raising

ORPHELIA Pharma raises 4 m€ to fund its commercial operations and clinical developments

https://initiative-octalfa.eu/wp-content/uploads/2020/01/2020-AK-board-EN-PR-200124-1.pdf
Orphelia Pharma

ORPHELIA Pharma announces the commercial launch of Kigabeq® in France

ORPHELIA Pharma announces the commercial launch of Kigabeq® in France

https://initiative-octalfa.eu/wp-content/uploads/2020/01/2020-Kigabeq-lancement-EN-PR-200107.pdf

Orega Biotech

Orega Biotech

Gilles Alberici, CEO and Jeremy Bastid, COO, will participate to the J.P. Morgan 38th Annual Healthcare Conference to be held 13-16 January 2020 in San Francisco, California, USA

https://www.jpmorgan.com/global/healthcare-conference

Happy new Year

Happy new Year

initiative Octalfa wishes you a happy new year 2020

https://initiative-octalfa.eu/wp-content/uploads/2020/01/Voeux-2020-EN.jpg
Orphelia Pharma

ORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma

ORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma

https://initiative-octalfa.eu/wp-content/uploads/2019/12/PR-ODD-US-Kimozo-en_191210.pdf

Newsletter november 2019

Newsletter november 2019

It has been a busy year for our Endowment Fund and Corporate Foundation!

https://initiative-octalfa.eu/wp-content/uploads/2019/12/Lettre-IDTA7-EN.pdf
Fondation

Two new projects supported by our Foundation

Two new projects supported by our Foundation

The 22th of november 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “APPEL” and “le Gai-Rire”,

https://initiative-octalfa.eu/wp-content/uploads/2019/12/191130-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf
Orphelia Pharma

ORPHELIA Pharma announces the granting of the Marketing Authorisation for Ivozall® from the European Commission

ORPHELIA Pharma announces the granting of the Marketing Authorisation for Ivozall® from the European Commission

https://initiative-octalfa.eu/wp-content/uploads/2019/11/pr-ivozall-191126-en-final.pdf

Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies

Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies

https://initiative-octalfa.eu/wp-content/uploads/2019/11/OREGA-Biotech_PR_191107.pdf
Orphelia Pharma

ORPHELIA Pharma and Veriton Pharma execute a license and distribution agreement for Kigabeq® in the United Kingdom

ORPHELIA Pharma and Veriton Pharma execute a license and distribution agreement for Kigabeq® in the United Kingdom

https://initiative-octalfa.eu/wp-content/uploads/2019/10/PR-Collaboration-Veriton_fr-final.pdf
Orphelia Pharma

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

https://initiative-octalfa.eu/wp-content/uploads/2019/10/Orphelia-CLM-final-en.pdf

First-in-class immune checkpoint inhibitor to be presented at SITC

First-in-class immune checkpoint inhibitor to be presented at SITC

https://initiative-octalfa.eu/wp-content/uploads/2019/10/OREGA-Biotech_PR_191001.pdf
Orphelia Pharma

ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®

ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

https://initiative-octalfa.eu/wp-content/uploads/2019/09/Orphelia-Ivozall-positive-opinion-2019_10_01-en.pdf

Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019

Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019

https://initiative-octalfa.eu/wp-content/uploads/2019/10/BAIKOWSKI_Acquisition_Mathym_SAS_EN-1.pdf
actu_institut

Two new projects supported by our Endowment Fund

Two new projects supported by our Endowment Fund

The 18th of september 2019, the board of directors of our Endowment Fund Dominique & Tom Alberici decided to support “Douleurs sans Frontières” and “Anyma”, two projects in Madagascar.

https://initiative-octalfa.eu/wp-content/uploads/2019/09/190930-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf
Fondation

Two new projects supported by our Foundation

Two new projects supported by our Foundation

The 18th of september 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Odynéo” and “Léthé Musicale”,

https://initiative-octalfa.eu/wp-content/uploads/2019/09/190930-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf
Orphelia Pharma

ORPHELIA announces Orphan Drug Designation for Kimozo®

ORPHELIA announces Orphan Drug Designation for Kimozo®

https://initiative-octalfa.eu/wp-content/uploads/2019/09/2019-OP-PR-190903-EN-final.pdf

Signature of a memorandum of understanding for the acquisition of Mathym SAS

Signature of a memorandum of understanding for the acquisition of Mathym SAS

Baikowski® has signed a memorandum of understanding for the acquisition, subject to the satisfaction of conditions precedent, of Mathym SAS, a company located at Champagne-au-Montd’Or in France.

https://initiative-octalfa.eu/wp-content/uploads/2019/08/baikowski_mathym_acquisition_eng_vd.pdf

Alizé Pharma 3

Alizé Pharma 3

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

https://initiative-octalfa.eu/wp-content/uploads/2019/07/190730-ALZ3-PR-ENG.pdf
Orphelia Pharma

ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in Germany

ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in Germany

ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.

https://initiative-octalfa.eu/wp-content/uploads/2019/07/2019-OP-PR-190716-EN-final.pdf
Orphelia Pharma

Collaboration between Gustave Roussy Cancer Centre and Orphelia Pharma

Collaboration between Gustave Roussy Cancer Centre and Orphelia Pharma

ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide

https://initiative-octalfa.eu/wp-content/uploads/2019/07/2019-Orphelia-Kimozo-collab-GR-en-final.pdf
image newsletter

Newsletter June 2019

Newsletter June 2019

This sixth newsletter is packed full of information seeing as the semester has been extremely busy for both the Dominique & Tom Alberici Foundation and our Endowment Fund.

https://initiative-octalfa.eu/wp-content/uploads/2019/07/Lettre-IDTA6_EN.pdf
Fondation

Three new projects supported by our Foundation

Three new projects supported by our Foundation

The 17th of may 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “le Sourire d’Onja”, “Sauvegarde 69”, and “Au-delà de nos Handicaps”,

https://initiative-octalfa.eu/wp-content/uploads/2019/08/190630-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Alberici Foundation Meetings

Alberici Foundation Meetings

We organised the Alberici Foundation Meetings on the 17th and 18th April to celebrate the 10th anniversary of the Alberici Foundation and our 100th project. Thank you to those who joined us on Wednesday evening. Some 280 of us attended the philanthropic evening of music and festivities, and it was great fun. Thanks also to those who support us but were unable to attend!

https://vimeo.com/346380067

Alizé Pharma 3

Alizé Pharma 3

Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019

https://initiative-octalfa.eu/wp-content/uploads/2019/07/190321-ALZ3-PR-EN-Endo.pdf
Millendo

Millendo Therapeutics

Millendo Therapeutics

Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome.

https://initiative-octalfa.eu/wp-content/uploads/2019/04/190319-MLND-Livoletide-Pivotal-Trial-Initiation-FINAL.pdf

JHAM3: Jumelage Handicap Aide Madagascar

JHAM3: Jumelage Handicap Aide Madagascar

The 3rd phase, JHAM3, launched in 2018 with a collection of items such as adaptive equipment, games, educational toys and books, stationery, school supplies, clothing and household linen.
The 33 m3 container left France on the 28th December en route for Toamasina in Madagascar, and we distributed the equipment to ten Malagasy organisations during our mission between the 3rd and 17th March.

https://vimeo.com/346362437
Millendo

Millendo Therapeutics

Millendo Therapeutics

Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia.

https://initiative-octalfa.eu/wp-content/uploads/2019/04/190314-Millendo-ENDO-2019-Curtain-Raiser-FINAL.pdf
Fondation Dominique et Tom Alberici

One new project supported by our Foundation

One new project supported by our Foundation

The 8th of february 2019, the board of directors of the Fondation Dominique & Tom Alberici decided to support the MIETE by helping to organise its Fest’Dif festival in Villeurbanne (Rhône) on the 5th and 6th July 2019, which aims to promote difference and diversity.

https://initiative-octalfa.eu/wp-content/uploads/2019/07/190208-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA_EN.pdf

January 2019 newsletter

January 2019 newsletter

Our Corporate Foundation and Endowment Fund are as busy as ever, with 4 projects supported this half-year and the effective implementation of the 3rd phase of the JHAM project (Jumelage Handicap Aide Madagascar – Madagascar Disability Support Twinning)…

https://initiative-octalfa.eu/wp-content/uploads/2019/07/Lettre-IDTA5_EN.pdf
Fondation Dominique et Tom Alberici

Two new projects supported by our Foundation

Two new projects supported by our Foundation

The 19th of october 2018, the board of directors of the Fondation Dominique & Tom Alberici decided to support Magie à l’hôpital for acquisition of digital and tactile adapted tablets for the hospitalized children at Necker Hospital, and Les Chiens du Silence (Dogs of Silence), which educates and provides earphone dogs to deaf or hard of hearing people.

https://initiative-octalfa.eu/wp-content/uploads/2018/12/181130-PROJETS-SOUTENUS-PAR-LA-FDTA-et-IDTA-_EN.pdf

Alizé Pharma 3

Alizé Pharma 3

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

https://initiative-octalfa.eu/wp-content/uploads/2019/07/181114_ALZ3-PR-ENG-1.pdf
Orphelia Pharma

ORPHELIA Pharma has been awarded a €1m loan from BPIFrance

ORPHELIA Pharma has been awarded a €1m loan from BPIFrance

https://initiative-octalfa.eu/wp-content/uploads/2019/07/181022-OP-PR-BPIFrance_ENG.pdf

Interleukin-17 patent granted in Europe

Interleukin-17 patent granted in Europe

https://initiative-octalfa.eu/wp-content/uploads/2019/05/72_OREGA_PR_181008.pdf
Orphelia Pharma

Granting of the marketing authorization for Kigabeq®

Granting of the marketing authorization for Kigabeq®

https://initiative-octalfa.eu/wp-content/uploads/2019/07/181001-OP-PR-181001-EN.pdf

JHAM2: Jumelage Handicap Aide Madagascar

JHAM2: Jumelage Handicap Aide Madagascar

The JHAM 2 project aims to implement a collective educational programme in 2017 following an observation phase.
A container has been sent in june 2017

https://vimeo.com/346379587
Téléphone : +33 (0)4 37 49 87 20 | Mail : initiative@octalfa.eu | Mentions légales | Politique d'utilisation des cookies

© Octalfa 2019

Go to Top